

No	IRAS No	REC Reference Number	Title	Target number of patients agreed?	Target range minimum	Target range maximum	Target date to recruit patients agreed?	Planned Recruitment end date	Total no of patients recruited at the agreed target date	Total no of patients recruited (current accrual)	Date study actually closed to recruitment at STH	Reason for closure of trial
1	114402	13/NW/0002	Prospective, randomised, controlled investigation comparing the safety and performance of 032-11 Surgical Haemostat 2g Applicator with FLOSEAL® Hemostatic Matrix as an adjunctive haemostat in cardiac surgery and thoracic aortic surgery.	Number Agreed	17	17	Not Available / Not Agreed		9	9	16/11/2016	Recruitment Finished
2	155632	15/LO/0040	Hypertrophic Cardiomyopathy Study - Phase 2 study to evaluate the safety and efficacy of a novel compound, GS-6615 on Exercise Capacity in Subjects with Symptomatic Hypertrophic Cardiomyopathy	Number Agreed	4	4	Date Agreed	31/12/2016	2	2	13/12/2016	Withdrawn By Sponsor
3	158613	14/NW/1294	A Phase III, multi-center, double-blind, placebo controlled, randomized withdrawal study of LCI699 following a 24 week, single-arm, open-label dose titration and treatment period to evaluate the safety and efficacy of LCI699 for the treatment of patients with Cushing's disease who are candidates for medical therapy.	Number Agreed	2	2	Date Agreed	17/04/2017	1	1	10/02/2017	Recruitment Finished

4	137191	13/LO/1328	A multicentre, randomized, double-blind, parallel group, active-controlled study to evaluate the efficacy and safety of LCZ696 compared to valsartan, on morbidity and mortality in heart failure patients (NYHA Class II-IV) with preserved ejection fraction	Number Agreed	6	6	Date Agreed	31/12/2016	5	5	31/12/2016	Recruitment Finished
5	167451	15/YH/0003	ZINN - Randomized, Doubleblind, Multicenter, Phase III Study Comparing the Efficacy and Safety of Retosiban Versus Atosiban Therapy for Women in Spontaneous Preterm Labor	Range Agreed	3	12	Date Agreed	16/06/2017	1	1	21/04/2017	Withdrawn By Sponsor
6	171812	15/LO/0448	A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Capecitabine and Cisplatin With or Without Ramucirumab as First-line Therapy in Patients With Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (RAINFALL)	Range Agreed	5	6	Date Agreed	31/12/2016	2	2	01/11/2016	Recruitment Finished
7	171675	15/LO/0337	A randomized, double-blind, placebo-controlled, prospective, multicenter, parallel group study to assess the safety and efficacy of macitentan in patients with portopulmonary hypertension	Range Agreed	2	3	Date Agreed	31/08/2017	0	0	31/08/2017	Recruitment Finished
8	172123	15/LO/0443	OPTIMIISM: Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma.	Number Agreed	10	10	Date Agreed	28/02/2017	2	2	29/03/2017	Recruitment Finished

9	183061	15/SC/0409	Safety and Efficacy of Abicipar Pegol in Patients with Neovascular Age-related Macular Degeneration.	Range Agreed	5	10	Date Agreed	30/11/2017	2	2	07/04/2017	Recruitment Finished
10	166537	14/WS/1146	Multicenter, randomized, double-blind, double-dummy, active-comparator, event-driven, superiority phase III study of secondary prevention of stroke and prevention of systemic embolism in patients with a recent Embolic Stroke of Undetermined Source (ESUS), comparing rivaroxaban 15 mg once daily with aspirin 100 mg (NAVIGATE ESUS)	Number Agreed	20	20	Date Agreed	30/09/2017	12	12	20/09/2017	Recruitment Finished
11	182401	15/LO/1074	"ExplorerTM3" A multi-centre, randomised, placebo controlled, double blinded, multiple dose trial investigating safety, pharmacokinetics and pharmacodynamics of concizumab administered subcutaneously to haemophilia A subjects. Trial ID: NN7415-4159	Number Agreed	1	1	Date Agreed	31/03/2017	0	0	05/10/2016	Recruitment Finished
12	185435	15/NW/0592	A randomised, double-blind, double-dummy, placebo-controlled, parallel-group multi-centre clinical proof-of-principle trial in adult subjects with newly diagnosed type 1 diabetes mellitus investigating the effect of NNC0114-0006 and liraglutide on preservation of beta-cell function.	Number Agreed	3	3	Date Agreed	11/08/2017	2	2	11/08/2017	Recruitment Finished

13	173712	16/NW/0218	A randomized, double-blind, placebo-controlled, two-period crossover study to assess the effect of inhaled QVA149 on global and regional lung function and gas exchange in patients with moderate to severe COPD	Number Agreed	6	6	Date Agreed	30/09/2017	4	4	11/08/2017	Recruitment Finished
14	198164	16/LO/0448	A Phase 2 study of LY2606368 in patients with extensive stage disease small cell lung cancer.	Number Agreed	1	1	Date Agreed	31/08/2017	0	0	17/01/2017	Recruitment Finished
15	202991	16/WM/0197	A multi-center, randomized, double-blind, placebo controlled, parallel group phase 2a study to assess the efficacy of RO5459072 in patients with primary Sjogren's syndrome.	Number Agreed	3	3	Date Agreed	31/08/2017	0	0	06/03/2017	Recruitment Finished
16	208246	16/EM/0320	A Randomized, Multicentre, Double-Blind, Placebo-Controlled Phase II Study of the Efficacy and Safety of Trastuzumab Emtansine in combination with Atezolizumab or Atezolizumab-Placebo in Patients with HER2-Positive Locally Advanced or Metastatic Breast Cancer who have Received Prior Trastuzumab and Taxane Base Therapy [KATE-2]	Number Agreed	2	2	Date Agreed	04/07/2017	1	1	07/08/2017	Recruitment Finished
17	208089	16/EM/0279	PIONEER-5: Efficacy and safety of oral semaglutide versus placebo in subjects with Type 2 diabetes and moderate renal impairment.	Number Agreed	5	5	Date Agreed	29/09/2017	3	3	29/09/2017	Recruitment Finished

18	157608	14/NE/1129	Pressure controlled Intermittent Coronary Sinus Occlusion as an adjunct to PCI in acute coronary syndrome. An observational study evaluating the effect of PICSO treatment concomitant to pPCI in patients with anterior non ST-segment Elevation Myocardial Infarction or following pPCI in ST-segment Elevation Myocardial Infarction.	Range Agreed	12	22	Date Agreed	30/06/2017	16	16	30/06/2017	Recruitment Finished
19	143226	14/LO/2182	STOP-HCC TS-103 A phase 3 clinical trial of intra-arterial TheraSphere in the treatment of patients with unresectable hepatocellular carcinoma	Number Agreed	2	2	Date Agreed	15/01/2018	6	6	04/09/2017	Recruitment Finished
20	164169	14/SS/1087	A Phase 3b, Multi-center, Open-label Trial to Evaluate the Long Term Safety of Titrated Immediate-release Tolvaptan (OPC4061, 30mg to 120mg/day, split dose) in Subjects with Autosomal Dominant Polycystic Kidney Disease	Number Agreed	1	1	Date Agreed	31/05/2017	1	1	28/02/2017	Recruitment Finished
21	174190	15/YH/0127	An open label extension study to investigate the long term safety, tolerability and efficacy of PF-02545920 in subjects with Huntington's disease who previously completed study A8241021	Number Agreed	1	1	Date Agreed	01/10/2017	3	3	06/04/2017	Withdrawn By Sponsor
22	174975	15/YH/0287	An open-label study of Dupilumab in patients with atopic dermatitis who participated in previous Dupilumab clinical trials.	Number Agreed	5	5	Date Agreed	28/02/2017	10	10	28/02/2017	Recruitment Finished

23	185434	15/WM/0327	Clinical evaluation of the Therapeutic Intra-Vascular Ultrasound (TIVUS) system for pulmonary artery denervation in patients with pulmonary hypertension. (TROPHY)	Range Agreed	1	5	Date Agreed	30/09/2017	6	6	14/09/2017	Recruitment finished
24	188788	15/LO/1670	Randomised, placebo-controlled, double-blind Phase 2 study of Patritumab (U3-1287) in combination with Cetuximab plus platinum-based therapy in first line setting in subjects with recurrent or metastatic squamous cell carcinoma of the head and neck.	Range Agreed	1	12	Date Agreed	21/07/2017	3	3	21/06/2017	Recruitment Finished
25	190662	15/YH/0538	Phase 3 Study Investigating the Efficacy, Safety and Tolerability of Dupilumab Monotherapy Administered to Adult Patients With Atopic Dermatitis (AD) Who Are Not Adequately Controlled With or Are Intolerant to Oral Cyclosporine or When This Treatment is Not Medically Advisable.	Number Agreed	5	5	Date Agreed	31/10/2016	7	7	03/10/2016	Recruitment Finished
26	187983	15/EM/0443	A Multi-Site, Open-Label Extension Trial of Oral RPC1063 in Relapsing Multiple Sclerosis	Number Agreed	7	7	Date Agreed	30/03/2017	7	7	30/03/2017	Recruitment Finished
27	166004	14/LO/2156	A Phase II Proof of Concept (PoC), Double-Blind, Randomised, Placebo-controlled Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VSN16R for the Treatment of Spasticity in Subjects with Multiple Sclerosis	Range Agreed	10	15	Date Agreed	19/10/2017	10	10	31/07/2017	Recruitment Finished

28	188506	16/NE/0028	SOLAR Study - An open-label, randomised Phase 3 efficacy study of ASP8273 vs Erlotinib or Gefitinib in first-line treatment of patients with Stage IIIB/IV Non-small Cell Lung Cancer tumours with EGFR activating mutations.	Range Agreed	1	3	Date Agreed	30/11/2017	2	2	05/05/2017	Withdrawn By Sponsor
29	189797	15/EE/0448	Clinical Trial of Nivolumab (BMS-936558) Combined with Ipilimumab Followed by Nivolumab Monotherapy as First-Line Therapy of Subjects with Histologically Confirmed Stage III (Unresectable) or Stage IV Melanoma. CheckMate 401: CHECKpoint pathway and nivolumab clinical Trial Evaluation 401.	Range Agreed	1	5	Date Agreed	30/06/2017	9	9	30/06/2017	Recruitment Finished
30	194393	16/EE/0011	A prospective, randomized, double blind, placebo-controlled, multicenter, phase 3 efficacy and safety study of oto-104 given as a single intratympanic injection in subjects with unilateral Meniere's disease.	Number Agreed	3	3	Date Agreed	30/11/2017	9	9	20/07/2017	Recruitment Finished
31	188945	15/EE/0418	CheckMate 451 – A randomised, multicentre, double-blind, Phase 3 study of Nivolumab, Nivolumab in combination with Ipilimumab, or placebo as maintenance therapy in subjects with extensive-stage disease small cell lung cancer (ED-SCLC) after completion of platinum-based first line chemotherapy	Range Agreed	2	4	Date Agreed	30/10/2019		3	08/09/2017	Recruitment Finished

32	200579	16/LO/0586	An open-label study to evaluate the efficacy and safety of ocrelizumab in patients with relapsing remitting multiple sclerosis who have a suboptimal response to an adequate course of disease-modifying treatment.	Number Agreed	3	3	Date Agreed	31/07/2017	10	10	24/02/2017	Recruitment Finished
33	186328	15/LO/1612	A Phase III, Randomized, Open-label, Controlled, Multi-Center, Global Study of First-Line MEDI4736 Monotherapy and MEDI4736 in Combination with Tremelimumab Versus Standard of Care Chemotherapy in Patients with Unresectable Stage IV Urothelial Cancer.	Number Agreed	2	2	Date Agreed	31/12/2016	8	8	27/12/2016	Recruitment Finished
34	172183	15/LO/0834	IMPAssion 130 - A Phase III, multicentre, randomised, placebo-controlled study of MPDL3280A (Anti-PD-L1 antibody) in combination with nab-Paclitaxel compared with placebo with nab-Paclitaxel for patients with previously untreated metastatic triple-negative breast cancer.	Range Agreed	2	4	Date Agreed	31/07/2017	3	3	29/05/2017	Recruitment Finished
35	205155	16/SC/0351	A Phase III, open-label, multicenter, three-arm, randomized study to investigate the efficacy and safety of cobimetinib plus atezolizumab and atezolizumab monotherapy vs. regorafenib in patients with previously treated unresectable locally advanced or metastatic colorectal adenocarcinoma.	Number Agreed	2	2	Date Agreed	30/04/2017	2	2	09/12/2016	Recruitment Finished

36	207331	16/EE/0243	A 6-month, multicenter, Phase 3, open-label extension safety study of OTO-104 given at 3-month intervals by intratympanic injection in subjects with unilateral Meniere's disease	Number Agreed	5	5	Date Agreed	30/06/2017	12	12	05/09/2017	Recruitment Finished
37	219556	17/EM/0014	Prospective Clinical Investigation for a Randomized, Controlled, Multicenter Non-inferiority Study Comparing Standard Wound Closure Technique with Drains (control) to Standard Wound Closure Techniques with TissuGlu® and No Drains (test) in Mastectomy.	Number Agreed	2	2	Date Agreed	29/09/2017	2	2	29/09/2017	Recruitment Finished